Itron remains a Buy as strong cash flow offsets soft FY25 guidance, likely due to delayed backlog, not lost sales. Read why ...

Zscaler shows strong growth, cash flow, and improving profitability despite dilution concerns, making it attractive for ...

The company said, “Biodexa has experienced net losses and significant cash outflows from cash used in operating activities over the past years as ...

Earnings are growing strongly and cash flow should wipe out debt next year, but the shares only trade on a forward PE ratio ...